Arboretum LifeSciences

What Arboretum LifeSciences does

Arboretum LifeSciences is a U.S.-based precision medicine company that delivers genetic testing programs to healthcare systems, with operations run through its wholly-owned subsidiary Arboretum Clinical, LLC, a CLIA-certified and CAP-accredited clinical laboratory headquartered in Cambridge, Massachusetts. The company's core technology combines monogenic variant detection with polygenic risk scores (PRS) to assess inherited risk for common conditions — specifically hereditary cancers (breast, ovarian, colorectal) and hereditary cardiovascular disease (familial hypercholesterolemia, arrhythmias, cardiomyopathies), with metabolic conditions referenced as a future vertical. Its stack includes a Research Participant Platform for electronic consent, survey capture, biospecimen coordination, and result return; a secure Research Analysis Environment for data curation and analytics; clinical-grade Pedigree Software for family history documentation; and a Genetic Test Ordering, Resulting, and Payment Processing Software platform used by healthcare providers. AI/ML capabilities — including generative AI, predictive analytics, recommendation engines, and knowledge retrieval — are deployed across variant interpretation, risk stratification, draft clinical communications, and biomarker-based clinical trial matching, with all AI-generated outputs reviewed by qualified personnel prior to delivery.

The business operates a hybrid revenue model across three streams: (1) transaction-based payer reimbursement for genetic testing services designed to meet clinical guidelines; (2) one-time and pay-as-you-go fees charged to individual users for direct-ordered Genetic Testing and Genetic Counseling services (with the underlying software provided at no charge); and (3) subscription/multi-year license fees paid by healthcare affiliates and institutional partners for access to certain software features under partnership agreements. Go-to-market is multi-channel: enterprise field sales targeting healthcare system decision-makers for turnkey program implementation, a self-serve/DTC channel for individual consumers, and channel-partner distribution through healthcare affiliates. The company also operates Sylva Biobank as a sub-brand, a longitudinal patient registry and biospecimen repository built in partnership with healthcare systems to support research, additional clinical result return, and clinical trial recruitment. Services are restricted to U.S.-based users, and the company is privately held with no disclosed funding history, no disclosed revenue, and no disclosed management team roster in the source data.

Name

Arboretum LifeSciences

Legal name

Arboretum LifeSciences, Inc.

Website

https://arboretum.bio

Company type

Private

Operating status

Operating

Headcount range

1–10 employees

Short description

Arboretum LifeSciences, via its CLIA-certified subsidiary Arboretum Clinical, delivers turnkey genetic testing programs combining monogenic and polygenic risk scoring for hereditary cancer and cardiovascular disease to U.S. healthcare systems, providers, and direct consumers.

Ownership category

akta.pro rank

Product category

Clinical Genetic Testing Services

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD)

akta.pro secondary industries

Genetic & Prenatal Testing Laboratories (HLAFAMAH), Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays (HLAAALAN), Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF)

Keywords

• Clinical genetic testing
• Precision medicine platforms
• Polygenic risk scoring
• Hereditary cancer screening
• Cardiovascular genetic testing

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Payer Reimbursement for Genetic Testing: Genetic testing services are designed for payer reimbursement with clear clinical guidelines. Testing for conditions where genetic information directly impacts clinical management and treatment decisions is reimbursable by insurance.
2. Individual User Fees for Clinical Services: Individual users pay fees for Genetic Testing and Genetic Counseling services. Individual users are not charged for access to the software platform for test ordering, resulting, or payment processing.
3. Healthcare Affiliate Software Licensing: Healthcare Affiliates and institutional users may be required to pay license fees for access to certain software features of the Service as set forth in the applicable partnership or license agreement.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels4 records

Core offering

Arboretum provides clinical genetic testing for common diseases (cardiovascular disease, cancer, metabolic conditions) using a proprietary method that combines monogenic variant detection with polygenic risk scores. Its CLIA-certified, CAP-accredited clinical laboratory offers Hereditary Cancer Tests, Hereditary Cardiovascular Tests, and Genetic Counseling Services, delivered via a turnkey platform to healthcare systems and directly to individuals. Supporting research products include the Research Participant Platform, Research Analysis Environment, and the Sylva Biobank research registry.

Product overview

Arboretum LifeSciences operates as a precision medicine company offering a platform-based approach to genetic testing and clinical research. The core offerings consist of the Research Participant Platform and Research Analysis Environment for research studies, paired with Arboretum Clinical's clinical services including Genetic Testing (Hereditary Cancer Tests and Hereditary Cardiovascular Tests), Genetic Counseling Services, and Pedigree Software. The company also operates Sylva Biobank as a longitudinal patient registry. All tests combine monogenic variant detection with polygenic risk scores, and the platform integrates software for genetic test ordering, resulting, and payment processing.

Differentiator

Problem solved

Functional benefit

Brands

• Arboretum Clinical: Clinical division providing genetic testing services, genetic counseling, and pedigree software tools for healthcare providers. CLIA-certified and CAP-accredited clinical laboratory.
• Sylva Biobank

Products and services

• Research Participant Platform A participant-facing platform for prospective observational research studies that enables electronic consent, survey capture, biospecimen collection coordination, return of research results, and matching participants to future research opportunities. For individuals who opt into Research Studies and Research Affiliates.
• Research Analysis Environment A secure analysis environment for storage, curation, and analysis of research data for research participants and research affiliates.
• Hereditary Cancer Tests Comprehensive genetic testing for inherited cancer risk across breast, ovarian, colorectal, and other hereditary cancer syndromes, combining monogenic variant detection with polygenic risk scores. Results inform screening schedules, chemoprevention planning, and surgical planning decisions. For individuals at risk for hereditary cancer and their healthcare providers.
• Hereditary Cardiovascular Tests Genetic testing for familial hypercholesterolemia, hereditary arrhythmias, cardiomyopathies, and inherited risk for common cardiac conditions, combining monogenic variant detection with polygenic risk scores. Results enable earlier diagnosis and more targeted treatment decisions. For individuals at risk for cardiovascular disease and their healthcare providers.
• Genetic Counseling Services Analysis and discussion of information about genes and other health factors, including biological samples, genetic information, and other health information. May be delivered remotely via telehealth using video, telephone, or secure messaging. For individuals receiving genetic testing and their referring providers.
• Sylva Biobank A biobank program operating in partnership with healthcare systems to provide tested patients with additional clinical test results, access to clinical trials, and opportunities to contribute to medical advancement. Functions as a longitudinal patient registry enabling translational research and trial recruitment.

Quantifiable outcome

• 1 in 20 people tested will have an actionable finding related to cancer
• +2 more outcomes

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability8 records

Feature6 records

Partnerships

Two partnerships are on record, tiered core and minor.

• Healthcare SystemscoreStrategic or Co-development PartnerArboretum partners with healthcare systems to implement genetic testing programs for cardiovascular disease, cancer, and metabolic conditions at scale. The turnkey approach integrates into clinical workflows while building patient registries that accelerate translational research and enable precision medicine trials. These partnerships help healthcare systems become leaders in personalized care.
• Sylva BiobankminorOthersSylva Biobank is referenced as a related entity. The company website navigation includes a link to Sylva Biobank, suggesting a related or affiliated biobanking operation for biospecimen storage and research purposes.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• Sema4 (now part of GeneDx): Sema4 (now operating under GeneDx) provides clinical genomic testing including hereditary cancer panels with a health system focus. It competes with Arboretum on hereditary cancer genetic testing and shares an enterprise health system sales motion.
• 23andMe: 23andMe provides direct-to-consumer genetic testing for common disease risk including selected hereditary conditions. Its consumer-facing model and emphasis on common disease risk partially overlap with Arboretum's hereditary cancer and cardiovascular testing, though its clinical positioning is less enterprise-focused.

Direct peers

• Helix: Helix operates a CLIA-certified clinical lab focused on hereditary disease genetic testing through health system partnerships, with similar reimbursement-aligned economics and a population genomics platform approach.
• Color Health: Color Health provides population-scale genetic testing for hereditary cancer and cardiovascular risk, with a similar B2B healthcare-system partnership model and CLIA-certified lab operations, making it the most direct competitor to Arboretum.
• Genome Medical: Genome Medical is a telehealth genetic counseling and clinical genomics service that integrates with health systems — directly comparable to Arboretum's genetic counseling offering and its health system implementation model.

Broad incumbents

• Myriad Genetics: Myriad is an established incumbent in hereditary cancer and cardiovascular genetic testing, with deep payer relationships and a broad test menu. It competes with Arboretum on the same clinical indications but operates at much greater scale and sales coverage.
• Natera: Natera provides genetic testing across reproductive health, oncology, and organ health, with an enterprise sales motion into hospital systems. Its oncology and broader hereditary testing offerings overlap with Arboretum's hereditary cancer and cardiovascular panels.
• Tempus: Tempus is a precision medicine company combining molecular testing with AI-driven analytics for oncology and broader disease areas. Its biomarker-based clinical trial matching and AI capabilities overlap with Arboretum's research platform and clinical trial services.
• Invitae: Invitae offers a broad genetic testing menu including hereditary cancer and cardiovascular panels, with an enterprise health system sales motion. It is a larger incumbent with overlapping clinical indications, though it has historically operated a different cost structure.
• Exact Sciences: Exact Sciences is a diagnostics incumbent with cancer screening and hereditary cancer testing offerings, comparable to Arboretum's hereditary cancer panels but operating at much larger commercial scale and with broader payer coverage.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/arboretum-lifesciences

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Arboretum LifeSciences